Daxor Corporation has announced a multicenter study published in the Journal of Cardiac Failure, revealing important findings about heart failure treatment using their Blood Volume Analysis (BVA) ...
The R0 resection rate after neoadjuvant bevacizumab (Bev) plus DOF versus DOF in local advanced gastric carcinoma (LAGC) and its association with circulating tumor cell (CTC). This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results